Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?

Kathryn L Laurie; Paul Lee; Alfred Rademaker; Todd A Alonzo; Yi-Cheng Wang; Bayard L Powell; Diana Wu; Richard Larson; Matthew Kutny; John Gregory; Nobuko Hijiya; James Feusner

doi:10.1002/pbc.29613

Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?

Pediatr Blood Cancer. 2022 Jun;69(6):e29613. doi: 10.1002/pbc.29613. Epub 2022 Mar 24.

Authors

Kathryn L Laurie¹, Paul Lee², Alfred Rademaker³, Todd A Alonzo⁴, Yi-Cheng Wang⁵, Bayard L Powell⁶, Diana Wu⁷, Richard Larson⁸, Matthew Kutny⁹, John Gregory¹⁰, Nobuko Hijiya¹¹, James Feusner¹²

Affiliations

¹ Department of Pediatric Hematology/Oncology, Goryeb Children's Hospital of Morristown Medical Center, Morristown, New Jersey, USA.
² AbbVie, Chicago, Illinois, USA.
³ Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁴ Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA.
⁵ Department of Biostatistics, University of Southern California, Los Angeles, California, USA.
⁶ Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.
⁷ St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
⁸ University of Chicago, Chicago, Illinois, USA.
⁹ Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹⁰ Novartis, East Hanover, New Jersey, USA.
¹¹ Division of Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, New York, USA.
¹² Division of Pediatric Hematology Oncology, Children's Hospital & Research Center Oakland, Benioff Children's Hospital Oakland, Oakland, California, USA.

Abstract

Objective: To compare outcomes of obese and nonobese pediatric patients with acute promyelocytic leukemia (APL) from the Cancer and Leukemia Group B trial (CALGB) 9710 and the Children's Oncology Group trial AAML0631.

Methods: Data including demographics, adverse events, overall and event-free survival (EFS) were analyzed.

Results: The prevalence of obesity was 34% on C9710 and 35% on AAML0631. There was significantly lower overall and EFS in the obese population on multivariable analysis on AAML0631 but not on CALGB 9710. Eleven patients died during therapy or in follow-up.

Conclusion: The prevalence of obesity is higher in pediatric patients with APL compared to the general population. The decreased EFS and OS in obese patients on AAML0631 suggest that the presence of obesity can influence outcomes using the most current treatment. These findings support the need for further research on the potential role of obesity in pediatric APL leukemogenesis.

Keywords: acute promyelocytic leukemia; obesity; pediatric.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Child
Disease-Free Survival
Humans
Leukemia, Promyelocytic, Acute* / drug therapy
Pediatric Obesity*
Prevalence
Prognosis
Treatment Outcome

Abstract

Publication types

MeSH terms

Grants and funding